AYTU BIOPHARMA, INC Proceeds from Long-Term Debt Issued
AYTU BIOPHARMA, INC (AYTU) reported Proceeds from Long-Term Debt Issued of $0 for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-09-22
- AYTU BIOPHARMA, INC proceeds from issuance of long-term debt for the quarter ending 2020-06-30 was $0.00.
- AYTU BIOPHARMA, INC proceeds from issuance of long-term debt for the quarter ending 2020-03-31 was $640.00K.
- AYTU BIOPHARMA, INC proceeds from issuance of long-term debt for the quarter ending 2019-06-30 was -$5.00M.
- AYTU BIOPHARMA, INC proceeds from issuance of long-term debt for the quarter ending 2019-03-31 was $0.00.
- AYTU BIOPHARMA, INC proceeds from issuance of long-term debt for fiscal 2026 was $0.00, a 100.00% decline from fiscal 2025.
- AYTU BIOPHARMA, INC proceeds from issuance of long-term debt for fiscal 2025 was $1.86M, a 85.72% decline from fiscal 2024.
- AYTU BIOPHARMA, INC proceeds from issuance of long-term debt for fiscal 2024 was $13.00M.
- AYTU BIOPHARMA, INC proceeds from issuance of long-term debt for fiscal 2020 was $640.00K.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month | Proceeds from Issuance of Long-term Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-K · filed 2026-09-22 | ||||
| 2025-06-30 | $1.86M 10-K · filed 2026-09-22 | ||||
| 2024-06-30 | $13.00M 10-K · filed 2025-09-23 | ||||
| 2020-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $640.00K derived: sum of 2 quarters · filed 2021-05-17 | $640.00K 10-K · filed 2020-10-06 | ||
| 2020-03-31 | $640.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-17 | $640.00K 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $0.00 10-Q · filed 2020-02-14 | ||||
| 2019-06-30 | -$5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | -$5.00M derived: sum of 2 quarters · filed 2020-10-06 | $0.00 10-K · filed 2020-10-06 | $5.00M 10-K · filed 2019-09-26 | |
| 2019-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-15 | $5.00M 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | $5.00M 10-Q · filed 2020-02-14 | ||||
| 2018-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26 | $0.00 derived: sum of 2 quarters · filed 2019-09-26 | $0.00 10-K · filed 2019-09-26 | ||
| 2018-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-14 | $0.00 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | $0.00 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |